Drug giant Sanofi to spend €400m a year in vaccine push

Plan aims to give it an edge in treating infectious diseases beyond Covid-19

Sanofi is bidding to keep up in the vaccine race.

French drugmaking giant Sanofi will invest €400m a year in messenger-RNA - or mRNA - technology to give it an edge in treating infectious diseases beyond Covid-19.

The company – which has a large manufacturing presence in Ireland - is bringing together about 400 workers from Massachusetts and France as part of an mRNA “centre of excellence” focused on everything from basic research to manufacturing, it said.